SRC and lung carcinoma: Dasatinib, a multi-kinase inhibitor targeting BCR-ABL, SRC, and c-KIT, has been shown not only to inhibit the growth of lung cancer-derived CAFs but also to revert their oncogenic phenotype to that of non-tumorigenic fibroblasts [43].